MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

ABSTRACT:

Background

Metastatic castration resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. Thus, there is an urgent need to develop more effective treatments beyond hormonal manipulation. We sought to identify activated kinases in mCRPC as therapeutic targets for existing, approved agents, with the goal of identifying candidate drugs for rapid translation into proof of concept Phase II trials in mCRPC.

Methods

To identify evidence of activation of druggable kinases in these patients, we compared mRNA expression from metastatic biopsies of patients with mCRPC (n = 101) to mRNA expression in localized prostate from TCGA and used this analysis to infer differential kinase activity. In addition, we

SUBMITTER: Nickols NG 

PROVIDER: S-EPMC6853839 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature